Core sedating antihistamine product information dating oosteuropa
In particular, management's expectations regarding the potential for loratadine could be significantly affected by the approach taken by managed care plans and the response of the patients to the OTC switch of loratadine and other risks and factors referred to in the Company's current Form 20-F on file with the Securities and Exchange Commission of the United States. are members of the Novartis AG (NYSE: NVS) group of companies, a world leader in healthcare with core businesses in pharmaceuticals, consumer health, generics, eye-care and animal health.Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health.Readers should not rely upon the information in these pages as current or accurate after their publication dates.Pseudoephedrine/loratadine (trade names Claritin-D, Clarinase, Clarinase Repetabs, Lorinase) is an orally administered combination drug used for the treatment of allergic rhinitis and the common cold. Pseudoephedrine/loratadine are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, sneezing, rhinorrhea, pruritus and lacrimation.This enables pharmacists the opportunity to convert their prescription-based consumers as well as those with existing Claritin prescription refills.This unique, behind the pharmacy counter marketing approach for a non-Rx drug will provide pharmacists with a time saving method to seamlessly offer prescription patients Geneva's lower cost, over-the-counter, generic version of Claritin.
The Group invested approximately CHF 4.3 billion (USD 2.8 billion) in R&D.The Novartis affiliate Geneva Pharmaceuticals, Inc. manufactures the product and has launched it as a non-prescription product.In March, the Novartis OTC business unit in the US will follow with the launch of Tavist Non-Sedating loratadine and private label loratadine both available for consumers, without prescription.A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core.The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.
Search for core sedating antihistamine product information:
During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of insomnia and dry mouth, both of which were commonly reported.